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Severe bile salt export pump deficiency: 82 different ABCB11
mutations in 109 families
Abstract
BACKGROUND & AIMS: Patients with severe bile salt export pump (BSEP) deficiency present as
infants with progressive cholestatic liver disease. We characterized mutations of ABCB11 (encoding
BSEP) in such patients and correlated genotypes with residual protein detection and risk of malignancy.
METHODS: Patients with intrahepatic cholestasis suggestive of BSEP deficiency were investigated by
single-strand conformation polymorphism analysis and sequencing of ABCB11. Genotypes sorted by
likely phenotypic severity were correlated with data on BSEP immunohistochemistry and clinical
outcome. RESULTS: Eighty-two different mutations (52 novel) were identified in 109 families (9
nonsense mutations, 10 small insertions and deletions, 15 splice-site changes, 3 whole-gene deletions,
45 missense changes). In 7 families, only a single heterozygous mutation was identified despite
complete sequence analysis. Thirty-two percent of mutations occurred in >1 family, with E297G and/or
D482G present in 58% of European families (52/89). On immunohistochemical analysis (88 patients),
93% had abnormal or absent BSEP staining. Expression varied most for E297G and D482G, with some
BSEP detected in 45% of patients (19/42) with these mutations. Hepatocellular carcinoma or
cholangiocarcinoma developed in 15% of patients (19/128). Two protein-truncating mutations conferred
particular risk; 38% (8/21) of such patients developed malignancy versus 10% (11/107) with potentially
less severe genotypes (relative risk, 3.7 [confidence limits, 1.7-8.1; P = .003]). CONCLUSIONS: With
this study, >100 ABCB11 mutations are now identified. Immunohistochemically detectable BSEP is
typically absent, or much reduced, in severe disease. BSEP deficiency confers risk of hepatobiliary
malignancy. Close surveillance of BSEP-deficient patients retaining their native liver, particularly those
carrying 2 null mutations, is essential.
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 Abstract  
Background and aims Patients with severe bile salt export pump (BSEP) deficiency present as infants with 
progressive cholestatic liver disease. We characterised mutations of ABCB11 (encoding BSEP) in such 
patients and correlated genotypes with residual protein detection and malignancy risk.  
Methods Patients with intrahepatic cholestasis suggestive of BSEP deficiency were investigated by 
single-strand conformational polymorphism analysis and sequencing of ABCB11. Genotypes sorted by likely
phenotypic severity were correlated with data on BSEP immunohistochemistry and clinical outcome.  
Results  Eighty-two different mutations (52 novel) were identified in 109 families (9 nonsense mutations, 10 
small insertions and deletions, 15 splice-site changes, 3 whole-gene deletions, 45 missense changes). In 7 
families only a single heterozygous mutation was identified despite complete sequence analysis. Thirty-two 
percent of mutations occurred in >1 family, with E297G and/or D482G present in 58% (52/89) of European 
families. On immunohistochemical analysis (88 patients), 93% had abnormal or absent BSEP marking. 
Expression varied most for E297G and D482G, with some BSEP detected in 45% (19/42) of patients with 
these mutations. Hepatocellular carcinoma or cholangiocarcinoma developed in 15% (19/128) of patients. Two 
protein-truncating mutations conferred particular risk; 38% (8/21) of such patients developed malignancy 
versus 10% (11/107) with potentially less severe genotypes (relative risk 3.7 [CL=1.7-8.1, p=0.003]).  
Conclusions With this study, >100 ABCB11 mutations are now identified. Immunohistochemically detectable 
BSEP is typically absent, or much reduced, in severe disease. BSEP deficiency confers risk of hepatobiliary 
malignancy. Close surveillance of BSEP-deficient patients retaining their native liver, particularly those 
carrying 2 null mutations, is essential.  
 Introduction  
Bile salt export pump (BSEP) deficiency is caused by mutations in ABCB11
1, 2
. The severity of BSEP deficiency 
varies from progressive early-onset
1
 to remitting and late-onset phenotypes
3-7
. Severe BSEP deficiency falls into 
the descriptive category of “progressive familial intrahepatic cholestasis” (PFIC)
8-12
, a heterogeneous group of 
autosomal recessive conditions that disrupt bile formation. BSEP deficiency is among disorders with low serum 
concentrations of γ-glutamyl transferase (γ-GT) activity despite conjugated hyperbilirubinaemia, as is familial 
intrahepatic cholestasis 1 (FIC1) deficiency caused by mutations in ATP8B1
13
. Both BSEP deficiency and FIC1 
deficiency exist worldwide. Their collective estimated Western European incidence is 1/50-70,000 births/year. 
BSEP, previously termed “sister of P-glycoprotein”
14
, is a member of the ATP-binding cassette (ABC) 
superfamily and P-glycoprotein / multidrug resistance (MDR/ABCB) subfamily of transporters
15, 16
. BSEP, 
expressed at the hepatocyte canalicular membrane, is the major exporter of primary bile acids
17
 
19
. It actively transports conjugated bile salts into biliary canaliculi against extreme concentration gradients. 
Liver disease in BSEP deficiency is ascribed to failed secretion and intrahepatocytic accumulation of toxic 
bile salts. Patients with the progressive form present as infants with high serum bile salts, pruritus, 
malabsorption, failure to thrive, jaundice and cholestasis. They develop fibrosis and end-stage liver disease 
before adulthood
20-22
. Partial external biliary diversion (PEBD) and ileal exclusion can relieve pruritus and, in 
some cases, slow disease progression
23-27
. However, most patients ultimately need orthotopic liver 
transplantation (OLT).  
We here present the mutations of ABCB11 in 109 families with severe BSEP deficiency.  
 Methods  
Families  
PFIC families were recruited through referral to King’s College London or the University of California, San 
Francisco. All procedures were conducted with informed consent as routine diagnostic investigations or under
an institutional-review-board–approved protocol. Referrers supplied clinical data. No patient had elevated 
serum concentrations of γ-GT activity. Other causes of neonatal hepatitis were excluded, including primary 
disorders of bile acid synthesis in most cases.  
Families were defined as affected by “severe” PFIC and included in the study if at least one family member 
presented in infancy with a low γ-GT cholestasis that progressed, with clinical and biochemical markers of 
cholestasis persistently abnormal (absent surgical intervention). They were excluded if cholestasis ever 
resolved completely.  
Selection for likely BSEP deficiency was based on clinical and histological data (specifically: Liver disease 
without the extrahepatic manifestations (pancreatitis, hearing loss, profound diarrhoea) characteristic of 
FIC1 deficiency, and exhibiting giant-cell hepatitis rather than bland cholestasis on histological assessment
21
)
Where possible, BSEP immunohistochemical analysis (30%)
2, 28, 29
 and/or microsatellite-based haplotype 
analysis
13, 30, 31 
were used. The resultant subgroup was analysed for ABCB11 mutations.  
One hundred and nine families (data and/or biopsy material available for 132 individuals) met the inclusion 
criteria of genetically proven severe BSEP deficiency (Supplementary Tables 1A-1E). Eighty-nine families were 
European (European, Australian, North American), 20 Central Asian/Arab, East Asian (Korean, Japanese, 
Chinese), South Asian (Indian, Pakistani) or African. BSEP immunohistochemistry was possible for 88 patients; 
clinical follow-up for malignancy was available in 128. In 7 families, clinical outcome and/or 
immunohistochemical results from a deceased sibling were included without mutational confirmation. In 5 
families only parental DNA was analysed. We have previously reported single  
mutations in 8 families
1, 2, 32
; the second mutant allele is now identified in each. Clinical observations in  
21 families have been reported previously
28, 29, 33
. These families are included to retain our population’s mutation 
profile.  
Sequence and genomic structure of ABCB11  
The 1321 amino-acid BSEP protein is encoded by ABCB11 on chromosome 2q24-31. ABCB11 spans a 108kb 
genomic region and is composed of 27 coding exons and one 5’ untranslated exon (designated 1-28). 
ABCB11 cDNA sequence (AF091582; AF136523; NM_003742) and genomic structure
1
 are available (National 
Center for Biotechnology Information;http://www.ncbi.nlm.nih.gov/). Mutation nomenclature
34
 follows Human 
Genome Variation Society recommendations (http://www.hgvs.org/mutnomen/). Previously published 
mutations have been revised accordingly.  
Mutation detection strategy  
Patients were initially screened by restriction-endonuclease (RE) digestion for recurrent changes at mutation 
hotspots and, depending on ethnicity, for population-associated changes. ABCB11 exons subsequently 
underwent single-strand conformation polymorphism (SSCP) analysis in 44 patients followed by sequence 
analysis of exons with identified mobility changes. Latterly this was replaced by primary sequencing. All exons 
were sequenced until clearly damaging, or previously known, mutations were identified on both alleles. 
Samples with novel missense changes were sequenced throughout. Mutations were confirmed using freshly 
extracted DNA from affected individuals and parental DNA (as available). Missense changes were 
distinguished from polymorphisms by several criteria. First was their absence from ethnically matched control 
panels of at least 300 alleles (published
35-38
, in public databases [http://pharmacogenetics.ucsf.edu/
39
], or within 
this study). Also considered was conservation across BSEP orthologues and MDR/ABCB homologues. Finally, 
predicted functional effects and differences in physical and chemical properties were assessed.  
Statistics  
The Statistics Calculator was used (http://www.cebm.utoronto.ca/practise/ca/statscal/). Chi-squared  
testing assessed differences between groups. Using the same data and calculator, relative risk and 95% 
confidence limits were similarly calculated.  
Immunohistochemistry  
Sections of formalin-fixed, paraffin-embedded liver, when available, were routinely stained and immunostained 
for BSEP using a polyclonal antibody raised in rabbit to the carboxy-terminal 21 amino acids of BSEP as 
previously described
19
. As a control for antigen preservation or protein-expression deficiencies not specific to 
BSEP, parallel sections were immunostained for a structurally similar canalicular ABC transporter, multidrug 
resistance-associated protein 2, using a monoclonal antibody raised in mouse (Signet/Bioquote, York, UK). 
Findings were evaluated by light microscopy as described
28, 29
. For 6 families immunohistochemical protocols 
used were as described
2
. BSEP marking was classified as normal, not detected or abnormal, where abnormal 
refers to either reduced intensity or focal absence. Immunohistochemical analysis preceded genetic analysis in 
30% of cases and followed it in the remainder. Abnormality was judged by two or more investigators, all blinded 
to genetic status.  
DNA extraction and polymerase chain reaction (PCR) amplification  
DNA was extracted from blood and tissue samples using standard protocols. PCR amplification was 
conducted using Taq DNA polymerase (New England Biolabs, Ipswich, MA) and Roche Fast Start PCR 
systems (Roche Diagnostics, Basel, Switzerland). Primer details provided in Supplementary Table 2.  
Microsatellite-marker typing Microsatellite-marker haplotype analysis was conducted across the ABCB11 
(2q24) and ATP8B1 (18q21) chromosomal regions in consanguineous families, or those with >2 affected 
children, to determine which gene was likely mutated. Marker loci were selected from genetic maps
40
 and 
developed from polymorphic repeats (Human Genome Mapping Project/Celera reference sequences; 
http://www.ncbi.nlm.nih.gov/). Primers were designed to allow multiplex analysis based on product size  
and fluorescent label (Supplementary Tables 3A/3B). Amplification products were separated on a 3100  
Avant Genetic Analyser, data were analysed using GeneMapper software (all Applied Biosystems, 
Foster City, CA) and haplotypes were constructed. Families with non-Mendelian segregation of 
mutations were investigated for deletions of the ABCB11 chromosomal region using microsatellite 
markers spanning 16.2Mb of chromosome 2.  
Restriction-endonuclease digestion  
RE digestion was used to identify common or recurring changes rapidly and to screen ethnically matched 
control panels for novel changes. Enzymes were selected using NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2/index.php; New England Biolabs or Roche Diagnostics). The common 
mutations E297G, D482G, R575X, R1153C and R1153H abolish HphI, FokI, FokI, BsrBI and BsrBI sites 
respectively, whilst G982R creates an AlwNI site. PCR-amplified exon-digestion products underwent 35% 
agarose gel electrophoresis (Supplementary Table 4).  
Single-strand conformation polymorphism analysis  
SSCP analysis was conducted using 12.5% acrylamide GeneGel Excel nondenaturing gels on a GenePhor 
Electrophoresis system (all Amersham Biosciences, Little Chalfont, UK), initially at 5
o
C and, if necessary for 
enhanced resolution, at 15
o
C. SSCP patterns were visualised by DNA silver staining (Amersham Biosciences). 
Products larger than 150bp were digested before analysis (as above).  
Sequencing  
PCR products were purified using the High Pure PCR purification system (Roche Diagnostics) before direct 
sequence analysis using the version 3.1 Dye Terminator cycle sequencing kit (Applied Biosystems) and 
electrophoresis on a 3100 Avant Genetic Analyzer. Data were analysed using Sequencher (Gene Codes, 
Ann Arbor, MI) or SeqScape (Applied Biosystems) software.  
 
Results  
Eighty-two different ABCB11 mutations were identified on 208 alleles in 109 families with severe BSEP 
deficiency (Tables 1-3; Figure 1; Supplementary Tables 1A-1E). Homozygosity, or compound heterozygosity, 
for ABCB11 mutations was completely concordant with disease expression in all families genotyped. Fifty-two 
mutations were novel. Eighteen previously reported severe mutations were not  
detected
1, 2, 5, 44-47  
.  
The 82 mutations identified (Tables 1-3, Figure 1) included 9 (11%; 4 novel) nonsense mutations, 10 (12%; 8 
novel) small insertions and deletions, and 15 mutations (18%; 6 novel) predicted to disrupt premRNA splicing. 
Sixteen (15%), 15 (14%) and 27 (25%) of the 109 families respectively, carried at least one such change.  
Whole-gene deletions occurred on a single allele in 3 families. The affected individuals in families 12 and 51 
appeared homozygous for a paternal mutation, the child in family 11 for a maternal mutation. Deletions 
confirmed and sized by haplotype analysis across the ABCB11 chromosomal region accounted for apparent 
homozygosity. In family 12 the flanking markers were D2S156 and D2S326; the deletion included up to 
12.5Mb of sequence
29
. In family 51 the deletion occurred between markers D2S399 and LRP2 (encoding low 
density lipoprotein-related protein 2) and included up to 2.24Mb of sequence. Exact breakpoints were not 
determined but both lay outside the coding and promoter regions of ABCB11. Extended haplotype analysis 
was not possible in family 11.  
The remaining 55% of mutations were missense substitutions (Table 3, Figure 1), which were present on at 
least one allele in 86 (79%) families. Forty-five different mutations (32 novel) were identified.  
Thirty-two percent (26) of the 82 mutations occurred, or had been reported to occur, in >2 families, with 16% 
(13) in >3 families. Most frequent were E297G and D482G, one or both of which were present in 58% (52/89)
of European families, and 15% (3/20) non-European families. E297G was detected in 34  
European families (41 alleles) and on one allele in both an African-American and a South Asian family.  
D482G occurred in 20 European families (25 alleles) and on one allele in a Central Asian/Arab family.  
In all but 10 families mutations were identified on both alleles. Of the remainder, in 2 families (107, 109), only 
maternal DNA was available; in one (108) available material was insufficient for complete sequence analysis; 
and in 7 (100-106) a second mutation was not detected despite complete sequence analysis.  
Of 99 families in which complete sequence analysis was possible and mutations were identified on both alleles
patients were homozygous for a single mutation in 36% (36/99) of cases and compound heterozygotes for 2 
different mutations in the remaining 64% (63/99). In 23 families homozygosity was associated with known 
consanguinity, whilst in 9 families, 2 copies of either E297G or D482G were found.  
To assess effects of specific ABCB11 genotypes on expression of immunohistochemically detectable BSEP 
protein, families were grouped according to whether they carried: 2 likely protein-truncating mutations; at least
one missense mutation (E297G or D482G excluded); at least one copy of E297G; at least one copy of D482G;
or only one identified mutation (Supplementary Tables 1A-1E).  
Immunohistochemical analysis was possible in 88 patients. All evaluated patients with 2 predicted 
protein-truncating mutations lacked demonstrable BSEP (Supplementary Table 1A). Variability in BSEP 
expression was greatest when either of the 2 common European mutations, E297G or D482G, was present on
one or both alleles (Supplementary Tables 1C-1E).  
Twenty-nine patients with at least one copy of E297G were immunostained: BSEP was not detected in 16 
(55%), was deficient in 12 (41%), and normal in one. For 14 patients with at least one copy of D482G, BSEP 
was not detected in 8 (57%), was abnormal in 3 (21%) and normal in 3 (21%). In total 45% (19) of 42 
immunostained patients with either of these mutations exhibited some BSEP expression. When all genotypes 
were considered, BSEP marking was absent in 72% (63/88), abnormal in 22%  
(19/88) and normal in 7% (6/88) of patients. Thus in total 93% (82/88) of all immunostained patients had 
abnormal or absent BSEP marking. Representative patterns are illustrated in Figures 2A-H.  
Outcome data (Supplementary Tables 1A-1E) confirmed that patients with BSEP deficiency are at 
considerable risk of hepatobiliary malignancy. Fifteen percent (19/128) of evaluable patients developed 
hepatocellular carcinoma or cholangiocarcinoma. Correlation with genotype identified those with 2 
protein-truncating mutations as being at particular risk. Thirty-eight percent (8/21) of patients with 2 predicted 
protein-truncating mutations developed malignancy versus 10% (11/107) of patients with potentially less 
severe defects, giving a relative risk of 3.7 (CL=1.7-8.1 p=0.003)  
 Discussion  
In keeping with the severe phenotype for which study subjects were selected, at least 45% (37) of the 82 
different mutations identified were predicted to result in premature protein truncation or failure of protein 
production (Tables 1, 2). Of the 10 deletions and insertions identified, 8 resulted in a frameshift and the 
introduction of a premature termination codon, whilst the other 2, in-frame deletions of 4 and 7 amino acid 
residues, were likely to lead to protein misfolding and degradation. Deletions were more frequent than 
insertions and typically involved the loss of one or 2 nucleotides. They were uniformly distributed throughout 
the gene (Figure 1). Most occurred within repeats or strings of nucleotides, suggesting origin by slippage or 
misalignment during DNA replication. The exception was exon 11, with 4 different deletions, 3 identified in the 
current study and one previously
44
. Of these, 3 arose between nucleotides 1100-1146, suggesting a deletion 
hotspot.  
Of the 15 splice-site changes identified, all but 2 involved the invariant GT or AG dinucleotides respectively at 
positions +1 / +2 of the 5’ donor and -2 / -1 of the 3’ acceptor splice sites. The change c.1435-13_1435-8del is 
also predicted to be damaging. The remaining change, c.2012-8T>G, disrupted the pyridimine tract of the 
already poorly conserved 3’ splice site of intron 16. Analysis of liver cDNA from a patient with this mutation (64) 
demonstrated skipping of exon 17 (unpublished data).  
The most common defects were missense mutations. Forty-five different substitutions were identified, with a 
missense mutation present on at least one allele in 79% (86/109) of families. However, whilst insertions, 
deletions, nonsense and splicing mutations are readily envisaged as damaging, the effect of a missense 
substitution is more difficult to predict. Changes in amino acid size, charge, polarity and hydrophobicity can all 
disrupt functional domains, protein structure, or affect protein processing and trafficking. At the nucleotide 
level, changes within the coding region may disrupt sequences that enhance or repress pre-mRNA splicing
50
. 
Substitutions were considered detrimental based on usual criteria (cf. Methods, mutation-detection strategy). 
In all but one case substitutions were not present in control panels. The exception was E297G, present on a 
single allele in 1/200 European Caucasian control chromosomes (http://pharmacogenetics.ucsf.edu)
39
, in 
keeping with the high frequency of this allele among European BSEP-deficiency patients.  
Degrees of conservation across orthologous and homologous proteins indicate the likely importance of a given
amino acid. All altered residues were conserved or, in 2 cases, replaced only by conservative substitutions, in 
BSEP orthologues in the mouse, rat and skate (Table 3). Eighty-seven percent of missense residues were 
conserved or substituted only conservatively in homologous MDR/ABCB family members (multidrug resistance
1 [MDR1] and multidrug resistance 3 [MDR3] proteins).  
At the biophysical level, 89% of missense mutations were predicted to change at least one aspect among 
charge, secondary- or tertiary-structure interactions, and hydrophobicity/polarity of BSEP (Table 3)
51
. Sixty 
percent of mutations significantly changed amino-acid residue charge, 51% size, and 69% 
hydrophobicity/polarity. Forty-three percent introduced or removed residues whose interactions typically 
determine secondary and tertiary protein structure. Of these, 22% introduced disulfide-bridge - forming 
cysteines or alpha-helix - breaking prolines; the remainder introduced or removed the hydroxylated residues 
serine or threonine.  
Whilst protein-truncating mutations were distributed uniformly throughout the protein (Figure 1), 60% of missense
changes clustered in the 2 highly conserved NBF domains (residues 414-610, 1072-1321
52
; 38% in NBF1 and 
22% in NBF2). Fourteen changes (31%) occurred within, or immediately adjacent to, the Walker motifs. Of the 
remainder, 7 (16%) occurred in the transmembrane (TM) domains; 5 of these introduced a charged residue into a
hydrophobic domain and, in 3 cases, simultaneously removed glycines, which stabilise alpha-helical TM spans. 
The intracellular loops contained 6 changes (13%), of  
which 3 including E297G, occurred in intracellular loop 2. No changes were identified in the extracellular loops 
although 2 have been reported
2, 44
.  
In the 93% (99/106) of families in which complete sequence analysis was possible, 2 mutant ABCB11 alleles 
were identified. In the remaining 7 families only a single mutation was identified despite extensive analysis. In 5 
cases the single mutations were splice site changes or E297G/D482G. In only 2 families were novel missense 
mutations identified (Q466K, N490D). Consistent with pathogenicity, both were at conserved sites in 
homologues and were absent from control populations. Q466K was associated with abnormal BSEP marking 
(detrimental). N490D was associated with normal marking; however, this mutation lies within NBF1, a region in 
which disease-associated mutations co-existed with retained BSEP marking (see below). Whilst we cannot 
exclude mutations in genes other than ABCB11 in this patient, analysis of ATP8B1 has identified no defects 
(unpublished data).  
Most cystic fibrosis patients in whom sequencing detects only one mutation harbour microdeletions of one or 
more exons
53
. This is likely also true for ABCB11. Such deletions, unless homozygous, will not be detected by 
genomic sequencing; exon-dosage analysis such as multiplex ligation-dependent probe amplification must be 
employed.  
Among the 82 different mutations identified in this study, 32% (26) occurred, or had been reported, in multiple
families, with 16% (13) present in >3 families. These likely represent both recurrent and founder mutations. The
most common natural mutation hotspots are cytosine-guanine (CpG) dinucleotides
54
.  
Thirty-three percent (18) of 54 missense and nonsense mutations occurred at these sites (Tables 1 and 3). 
Ten mutations occurred in multiple families: R470Q, R832C
33
, R948C, A1110E and R1231Q
48
 have now been 
reported in 2 families; R1090X
2
 in 3 families; G982R
1, 2
, R1153C
1, 47
and R1153H in 4 families; and R575X in 6 
families
1, 2, 32, 45 
.  
Six common missense and nonsense changes occurred at non-CpG sites: R520X and A588V
33
 in 2  
European families and E1302X and I541L
33, 49
 in 3 European families each. By far most common, however, were 
E297G and D482G, at least one of which was present in 58% (52/89) of European and in 15% (3/20) of 
non-European families. The population distribution of E297G, most frequent along the North European 
seaboard, suggests origin in Northern Europe and spread southwards through Central and Eastern Europe. 
The mutation was also found in one South Asian and one African-American family. In contrast, D482G likely 
originated in Central or Eastern Europe, with cases identified in Polish, Austrian, Slovak, Czech, Hungarian and 
Russian families. This mutation was also present in a Greek and an Iranian family.  
Five common insertions and deletions were identified, with c.379delA in 3 apparently unrelated Arab families
and c.1145-1165del, c.1583_1584delTA, c.1941delA
28
 and c.2787_2788insGAGAT
5
 in 2 European families 
each. Five common splice-site mutations occurred, with c.611+1G>A
28
; c.20128T>G
28
; c.2178+1G>A
4, 28
; 
c.2343+1G>T
29
 and c.3213+1delG
2
 in respectively 2, 7, 4, 3 and 2 families. Geographical distributions 
suggest that most are likely founder mutations.  
Mutation clusters were also observed. For NBF domains this likely reflects functional importance. At other sites 
both mutations and polymorphisms clustered within the same or adjacent codons, suggesting sequence 
instability or mutagen interaction. Mutation clusters include Y472C, Y472X
28
 and I541L
33, 49
/ I541T. Four different 
changes occurred at, or adjacent to, the 5’ splice site of intron 9: R303K, c.908+1delG
1, 33
, c.908+1G>T
28 
and 
c.908+1G>A. Three occurred at the 5’ splice site of intron 18: c.2178+1G>A
4, 28
, c.2178+1G>T and 
c.2178+1G>C.  
BSEP deficiency represents a phenotypic continuum between progressive early-onset
1
 disease and 
remitting, and late-onset, phenotypes
3-7
. Eleven different mutations have been reported in BSEP deficiency 
disease clinically assessed as intermediate
6
 or mild in severity
4,5,7
. Three of these, E297G, A570T, and 
c.2178+1G>A, have also been found in PFIC. In milder disease, missense mutations  
predominate over those that result in protein truncation or a failure of protein production; more mutations occur
in less conserved regions, e.g., intracellular loops, than in the NBFs; and mutated residues are less likely to be
conserved. Compound heterozygosity for both a severe and a mild mutation may result in mild disease. That 
homozygosity for E297G is seen in discrepant phenotypes strongly indicates that environment and genetic 
background also play roles.  
Immunohistochemistry appears valuable in identifying likely BSEP deficiency, as many patients studied 
exhibited little or no detectable BSEP at the hepatocyte canaliculus
2, 28, 29
. An anti-C-terminal antibody can be 
expected not to mark when protein is absent or when a misfolded or truncated “partial protein” is expressed. 
Immunoreactivity may depend on tissue processing, disease stage, therapeutic intervention and disease 
mechanism. These factors are to be considered in interpreting immunohistochemical results.  
Immunohistochemically detectable BSEP expression does not exclude functional BSEP deficiency. 
Twenty-eight percent (25/88) of patients analysed exhibited some degree of BSEP marking; in 6 expression 
was considered normal. Residual marking was most striking in patients with E297G or D482G, with some seen 
in 45% (19/42) of patients carrying at least one of these alleles. Ten additional missense mutations were 
associated with detectable BSEP marking (Supplementary Tables 1B-1E, Figures 2A-2H). Abnormal marking 
was seen with L50S, Q466K, N515T, R517H, I541L, and F548Y, and normal with N490D, G562D, R832C, and 
A1110E. As most of these were found in combination with E297G or D482G their individual effects could not be 
assessed. Nine of the 12 mutations occurred within the highly conserved NBFs (8 within NBF1, 4 within or 
adjacent to Walker motifs) suggesting an effect on protein function. Abnormal (typically reduced) marking may 
also result from decreased protein production or defective sorting or instability of an otherwise functional 
protein. Such patients in particular may be amenable to therapeutic interventions such as PEBD or the use of 
pharmacological agents which enhance BSEP cell-surface expression, e.g., 4-phenylbutyrate
55
.  
The above notwithstanding not to detect BSEP immunohistochemically, or to demonstrate BSEP  
deficiency, is highly useful. Deficiency or absence of BSEP expression could be demonstrated in 93%  
(82) of the 88 patients in whom immunohistochemical study was possible. As some patients were selected 
for mutational analysis in part because they lacked immunohistochemically detectable BSEP, the exact 
sensitivity of this technique could not, however, be assessed.  
We have previously shown that BSEP deficiency is associated with increased susceptibility to hepatobiliary 
malignancy
28, 29
. In this study 38% (8/21) of patients with 2 predicted protein-truncating mutations 
(Supplementary Table 1A) developed either hepatocellular carcinoma or cholangiocarcinoma, versus 10% 
(11/107) of other patients (Supplementary Tables 1B-1E), giving a relative risk of 3.7 (1.78.1, p=0.003). Of the 
other 13 patients with 2 protein-truncating mutations, all but 3 have undergone OLT or died of non-malignant 
disease. The 3 who retain their native livers (ages 2.4yrs, 7yrs and 16yrs) are under close observation. Without 
OLT the incidence of malignancy in patients with 2 protein-truncating ABCB11 mutations is expected to exceed 
that observed in this study. BSEP-deficient patients, in particular those carrying 2 predicted null mutations, who
retain their native liver require close surveillance for hepatobiliary malignancy.  
 Legends  
Table 1: Nonsense mutations, deletions and insertions  
Abbreviations: EU, European Caucasian; CA/AR, Central Asian/Arab; EA, East Asian; AF, African.  
Table 2: Splice site mutations  
Abbreviations: EU, European Caucasian; CA/AR, Central Asian/Arab. *Denotes studies in which 
mutations are associated with mild disease.  
Table 3: Missense mutations  
Abbreviations: EU, European Caucasian; CA/AR, Central Asian/Arab; EA, East Asian; SA, South Asian; AF, 
African; m/r/s bsep, mouse/rat/skate bsep; IC, intracellular loop; Hyd/Pol, hydrophobicity or polarity; NBF, 
nucleotide-binding fold; NBF/TM, location between NBF domain and TM region; NH2 Term, amino terminal; 
MDR1/3, multidrug resistance proteins 1/3; TM, transmembrane domain. Unless specified all proteins are 
human. *Denotes studies in which mutations are associated with mild disease.  
Figure 1: Schematic representation of BSEP with location of mutations identified in this study. BSEP is a full 
ABC transporter
41
 composed of 2 homologous halves, arranged in tandem and joined by a linker region. Each 
half comprises a hydrophobic membrane domain, containing 6 hydrophobic transmembrane (TM) spans, and 
a cytoplasmic nucleotide binding fold (NBF). The NBFs contain the Walker A/B motifs, characteristic of all 
nucleotide-binding proteins, and ABC signature, stacking aromatic, D, H and Q, loops which define ABC 
proteins
42
. The NBFs bind and hydrolyse ATP to generate transport-driving energy, whilst the TM domains form 
the pore and define substrate specificity. Schematic generated using TOPO2 software 
(http://www.sacs.ucsf.edu/TOPO-run/wtopo.pl). Protein topology predicted by comparison with MDR1
43
. TM 
spans predicted to fit the accepted topology using TopPred II (http://www.expasy.ch/tools/). Singly mutated 
residues represented as coloured  
residues; founder/recurrent mutations indicated by arrows. For insertions/deletions the affected residue  
is indicated, for splice sites the adjacent amino acid. Key: Blue-missense; Red-stop; Green 
deletion/insertion; Orange-splice-site; Black-several different mutations at this site; Purple-Walker A, B and 
ABC motifs.  
Figure 2: Expression patterns on immunostaining for canalicular transporters bile salt export pump 
(BSEP) and multidrug resistance-associated protein 2 (MRP2). Avidin/biotin technique; all sections 
counterstained with haematoxylin.  
A. Normal BSEP marking of control liver without cholestasis. Anti-BSEP antibody marks an orderly 
canalicular network. Original magnification 200x.  
B. Normal MRP2 marking of control liver without cholestasis. Anti-MRP2 antibody marks an orderly 
canalicular network. Original magnification 200x.  
C. Absent BSEP marking in patient 4, homozygote for ABCB11 mutation yielding Y472X. Hepatectomy for 
cirrhosis with hepatocellular carcinoma, age 1 year. No marking for BSEP is seen. Original magnification 
200x.  
D. MRP2 marking in patient 4 (see C, above). Anti-MRP2 antibody highlights canalicular network. 
Original magnification 200x.  
E. BSEP marking in patient 29, homozygote for ABCB11 mutation yielding R832C. Hepatectomy for 
cirrhosis, age 3 years. The canalicular network is delineated well. Original magnification 200x.  
F. MRP2 marking in patient 29 (see E, above). Anti-MRP2 antibody highlights canalicular network. 
Original magnification 200x.  
G. BSEP marking in patient 47b, compound heterozygote for ABCB11 mutations yielding L50S and A1110E. 
Hepatectomy for cirrhosis with hepatocellular carcinoma, age 6 years. Canalicular marking for BSEP is 
abnormal; it is present only focally (arrows) and is assessed as both faint and patchy. Original magnification 
200x.  
H. MRP2 marking in patient 47b (see G, above). Reaction product (anti-MRP2 antibody) highlights centres 
of hepatocellular rosettes as well as canalicular network. Hepatectomy. Original magnification 200x.  
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Nucleotide change  Exon  Predicted effect  Mutation type  CpG 
Site  
E
oTotal number of 
families in which 
identified  
Families in 
current 
study  
c.74C>A  2  p.Ser25X  Nonsense  No  1  18  E
 
c.379delA  5  p.Thr127HisfsX6  Deletion  3  1-3  C
 
c.1101_1102delAG  11  p.Val368ArgfsX27  Deletion  1  52  E
 
c.1139delT  11  p.Leu380TrpfsX18  Deletion  1  13  E
 
c.1145_1165del  11  p.Ala382_Ala388del  Deletion  2  14, 15  E
c.1416T>A  13  p.Tyr472X  Nonsense  No  1  4  C
c.1558A>T  14  p.Arg520X  Nonsense  No  2  59, 81  E
 
c.1583_1584delTA  14  p.Ile528SerfsX21  Deletion  2  53, 54  E
c.1723C>T  15  p.Arg575X  Nonsense  Yes  6  E
12, 13, 17, 
19, 37  
 
c.1941delA  16  p.Gly648ValfsX6  Deletion  2  16, 55  E
c.2316T>G  19  p.Tyr772X  Nonsense  No  1  5  E
 
c.2787_2788insGAGAT  22  p.Lys930GlufsX79  Insertion  2  36  E
 
 
 
 
c.2906_2917del  23  p.Lys969_Lys972del  Deletion  1  56  E
c.3268C>T  25  p.Arg1090X  Nonsense  Yes  3  17, 60  E
 
c.3438delA  26  p.Val1147X  Deletion  1  57  E
 
c.3491delT  26  p.Val1164GlyfsX7  Deletion  1  58  E
c.3643C>T  27  p.Gln1215X  Nonsense  No  1  38  E
c.3703C>T  27  p.Arg1235X  Nonsense  Yes  1  6  E
Table 1: Nonsense mutations, deletions and insertions in ABCB11  c.3904G>T  28  p.Glu1302X  Nonsense  No  3  20, 21, 61  E
 Table 2: Splice site mutations in ABCB11 
 
Splice site  Nucleotide change  Ethnic origin  
Previous 
reports  
Exon 
skippable 
in frame  
Total number of 
families in which 
identified  
Families 
in current 
study  
 
3’ Intron 5  c.390-1G>A  No  1  8  CA / AR  
5’ Intron 7  c.611+1G>A  No  2  21, 62  EU  28  
5’ Intron 9  c.908+1delG  No  1  39  EU  1, 33  
5’ Intron 9  c.908+1G>T  No  1  107  EU  28  
 
5’ Intron 9  c.908+1G>A  No  1  82  CA / AR  
3’ Intron 13  c.1435-13_1435-8del Yes  1  63  EU  28  
3’ Intron 16  c.2012-8T>G  No  7  EU  
14-16, 
40, 64, 
65, 100,  
28  
 
5’ Intron 18  c.2178+1G>T  No  1  19  EU  
18, 20, 
41, 42  
5’ Intron 18  c.2178+1G>A  No  4  EU  4*, 28  
 
5’ Intron 18  c.2178+1G>C  No  1  43  EU  
 
3’ Intron 18  c.2179-2A>G  Yes  1  11  EU  
5’ Intron 19  c.2343+1G>T  Yes  3  EU  
44, 66, 67  29  
5’ Intron 19  c.2343+2T>C  Yes  1  9  EU  28  
 
3’ Intron 21  c.2611-2A>T  Yes  1  10  CA / AR  
5’ Intron 24  c.3213+1delG  No  2  7  EU, CA / AR  2  
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curre
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Total number 
of families in 
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identified  
Conservation 
B S E P m b s 
e p r b s e p s 
b s e p  Change in: S 
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S h a p e  
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  c.149T>C  p.Leu50Ser  4  No  NH2 Term  Y Y L L L L  L 1  47  
 Y
  
Y
  
Y
 c.470A>G  p.Tyr157Cys  6  No  TM2  Y Y Y Y Y Y  1  49  
  Y
  c.725C>T  p.Thr242Ile  8  No  TM4  Y T T T T  T  T 1  41  
 c.890A>G  p.Glu297Gly  9  No  IC2  Y
  
Y Y E E E E  Q
  
Q
 
67  
51-80, 
102-10
109  
    R
  
N
 c.908G>A  p.Arg303Lys  9  No  IC2  R R R R  1  22  
R
  
E
 
Y
  1  83  Y Y Y R R R R  c.937C>A  p.Arg313Ser  10  Yes  IC2  
 Y
  
G
  
G
 Y Y 1  50  c.980G>A  p.Gly327Glu  10  No  TM5  G G G G  
   A
  
A
 c.1168G>C  p.Ala390Pro  11  No  TM / NBF  Y A A A A  1  68  
  G
  
G
 c.1229G>A  p.Gly410Asp  12  No  TM / NBF  Y Y G G G G  1  84  
    P
  
P
 c.1238T>G  p.Leu413Trp  12  No  TM / NBF  L L L L  1  45  
 Y
  c.1388C>T  p.Thr463Ile  13  No  Adj Walker A  Y Y T T T T  T  T 1  38  
 
 
 
   Q
  
Q
  
Q
  
Q
  
Q
  c.1396C>A  p.Gln466Lys  13  No  Adj Walker A  Y E  1  101  
   c.1409G>A  p.Arg470Gln  13  Yes  Adj Walker A  Y R
  
R
  
R
  
R
  
R
  
R
  
2  23, 85 
 Y
  c.1415A>G  p.Tyr472Cys  13  No  Adj Walker A  Y Y Y 
Y
  
Y
  Y  Y  Y  1  46  
 Y
  Y Y c.1442T>A  p.Val481Glu  14  No  NBF1  V L  L  L  V  I 1  36  
  c.1445A>G  p.Asp482Gly  14  No  NBF1  Y Y D
  
D
  
D
  
D
  
D
  
D
  
22  
81– 99,
Y
  
R
  
R
  
R
  
R
  
R
  
R
  c.1460G>C  p.Arg487Pro  14  Yes  NBF1  Y Y Y 1  24  
   N
  
N
  
N
  
N
  
N
  
N
  1  106  c.1468A>G  p.Asn490Asp  14  No  NBF1  Y 
 Y
  c.1535T>C  p.Ile512Thr  14  No  NBF1  Y Y I I  I  I  I  I 1  46  
  
c.1544A>C  p.Asn515Thr  14  No  NBF1  Y Y N  
N
  
N
  
N
  
N
  
N
  1  86  
  R
  
R
  
R
  
R
  
R
  
R
  1  87  c.1550G>A  p.Arg517His  14  Yes  NBF1  Y Y 
    
c.1621A>C  p.Ile541Leu  14  No  NBF1  I I  I  I  I  I 3  25, 39 
 Y
  c.1622T>C  p.Ile541Thr  14  No  NBF1  Y Y I I  I  I  I  I 1  44  
    
c.1643T>A  p.Phe548Tyr  15  No  Adj ABC  F F  F  F  F  F 1  69  
  G
  
G
  
G
  
G
  
G
  
G
  c.1685G>A  p.Gly562Asp  15  No  ABC  Y Y 1  88  
   
c.1708G>A  p.Ala570Thr  15  Yes  ABC / Walker B  Y A A  
A
  A  A  A  1  26  
 
 
 
   A
  
A
 c.1763C>T  p.Ala588Val  15  No  Adj Walker B  Y A A  A  A  2  70, 89 
 Y
  
G
  
G
  
G
  
G
  
G
  
G
 Y Y 1  27  c.2272G>C  p.Gly758Arg  19  No  NBF / TM  
 Y
  
G
  
G
  
G
  
G
  
G
  
G
 c.2296G>A  p.Gly766Arg  19  Yes  TM7  Y Y 1  28  
c.2494C>T  p.Arg832Cys  21  Yes  IC3  Y
  
Y Y Y R
  
R
  
R
  
R
  
R
  
R
 
2  29, 90 
Y
  c.2576C>G  p.Thr859Arg  21  No  IC3  Y Y Y T T  T  T  T  T 1  43  
Y
  
R
  
R
  
R
  
R
  
R
  
R
 c.2842C>T  p.Arg948Cys  23  Yes  IC4  Y Y Y 2  42, 71 
   N
  
N
  
N
  
N
  
H
  
H
 c.2935A>G  p.Asn979Asp  23  No  TM11  Y 1  30  
 c.2944G>A  p.Gly982Arg  23  Yes  TM11  Y
  
Y Y G
  
G
  
G
  
G
  
G
  
G
 
4  31, 37 
M
  
V
 
Y
  1  91  Y Y Y T T  T  T  c.3086C>A  p.Thr1029Lys  24  No  TM12  
 Y
  
A
  
A
 c.3329C>A  p.Ala1110Glu  25  Yes  Adj Walker A  Y Y A A  A  A  2  47, 72 
R
  
R
  
R
  
R
  
R
  
R
 
Y
  1  32  Y Y Y c.3382C>T  p.Arg1128Cys  25  Yes  Adj Walker A  
c.3457C>T  p.Arg1153Cys  26  Yes  NBF2  Y
  
Y Y Y R
  
R
  
R
  
R
  
R
  
R
 
4  73  
  R
  
R
  
R
  
R
  
R
  
R
 4  33, 34, c.3458G>A  p.Arg1153His  26  Yes  NBF2  Y Y 
   
c.3460T>C  p.Ser1154Pro  26  No  NBF2  Y S S  
A
 S  S  A  1  50  
 
 
Table 3: Missense mutations in ABCB11  
 
   
c.3628A>C  p.Thr1210Pro  27  No  Adj ABC  Y T T  T  T  T  T 1  35  
  R
  
R
  
R
  
R
  
R
  
R
  1  92  c.3691C >T  p.Arg1231Trp  27  Yes  ABC / Walker B  Y Y 
   R
  
R
  
R
  
R
  
R
  
R
  c.3692G>A  p.Arg1231Gln  27  Yes  ABC / Walker B  Y 2  48  
    
c.3724C>A  p.Leu1242Ile  27  No  Walker B  L L  L  L  L  L 1  45  
 Y G G
 
G
  
G
  
G
  
Gc.3892G>A  p.Gly1298Arg  28  No  NBF2  Y Y 1  49  
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